Physician profile
Michael T Lin
NPI 1164436820
$27,745.44
in general payments reported to CMS, 2019-2025
49 companies · $3,862 in 2025
The $3,862 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,992 · 2020: $719 · 2021: $1,634 · 2022: $2,305 · 2023: $4,079 · 2024: $6,155 · 2025: $3,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,829.59 |
| Education | $265.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apyx Medical Corporation | $6,998.20 | 2019 | |
| Abbvie INC. | $3,583.00 | 2019-2025 | |
| Strata Skin Sciences, INC. | $1,721.22 | 2022-2025 | Xtrac |
| Genzyme Corporation | $1,349.49 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $1,194.03 | 2019-2025 | Ilumya, Winlevi |
| Organogenesis INC. | $1,191.92 | 2020-2025 | Puraply, Cygnus Dual, Affinity |
| Janssen Biotech, INC. | $1,060.38 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,040.14 | 2019-2025 | |
| Amgen INC. | $1,038.34 | 2019-2025 | Otezla, Otezla |
| Ucb, INC. | $950.06 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $949.98 | 2019-2025 | |
| Biofrontera INC. | $930.63 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $889.58 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $646.85 | 2021-2025 | Opzelura, Opzelura |
| Allergan, INC. | $606.54 | 2019-2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $546.33 | 2019-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $455.60 | 2023-2025 | Sotyktu |
| Merz North America, INC. | $363.71 | 2022-2023 | Xeomin |
| Arcutis Biotherapeutics, INC. | $232.41 | 2023-2025 | Zoryve |
| Bard Peripheral Vascular, INC. | $225.97 | 2023 | Venclose Maven Catheter, Rotarexs 6 F X 135 Cm, Ultraverse 014 |
| Celgene Corporation | $202.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.82 | 2022-2025 | Spevigo, Cyltezo |
| Organon LLC | $161.89 | 2025 | Vtama |
| Leo Pharma INC. | $148.75 | 2021-2025 | Adbry, Spevigo, Anzupgo |
| Revance Therapeutics, INC. | $140.64 | 2024 | Daxxify |
| Lnhc, INC | $124.99 | 2025 | Zelsuvmi |
| Regeneron Healthcare Solutions, INC. | $93.53 | 2019-2025 | Libtayo, Dupixent |
| Almirall LLC | $91.76 | 2019-2025 | Klisyri |
| Dermira, INC. | $65.62 | 2019-2020 | |
| Smith+Nephew, INC. | $59.57 | 2024-2025 | Collagenase Santyl, Grafix |
| Botanix Sb INC | $57.16 | 2025 | Sofdra |
| Boston Scientific Corporation | $51.15 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $51.07 | 2019 | |
| Sanofi-Aventis U.S. LLC | $45.58 | 2019 | |
| Dusa Pharmaceuticals, INC. | $44.07 | 2019 | |
| Verrica Pharmaceuticals INC. | $41.47 | 2024 | Ycanth |
| Medtronic, INC. | $39.18 | 2023-2024 | Accurian |
| Epi Health, LLC | $28.85 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $24.53 | 2019-2024 | |
| Genentech USA, INC. | $22.60 | 2019 | |
| Dermavant Sciences, INC. | $22.06 | 2023 | Vtama |
| Phadia US INC. | $21.74 | 2021 | |
| Journey Medical Corporation | $19.88 | 2023 | |
| Medimetriks Pharmaceuticals, INC. | $19.63 | 2022 | |
| Taro Pharmaceuticals USA, INC. | $13.26 | 2019 | |
| Prugen, INC. Pharmaceuticals | $12.91 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.